These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 34794376)

  • 1. Outcomes of endoscopic submucosal dissection for gastroesophageal reflux disease (ESD-G) for medication-refractory gastroesophageal reflux disease: 35 cases underwent ESD-G including 15 cases followed more than 5 years.
    Ota K; Takeuchi T; Kojima Y; Sugawara N; Nishida S; Iwatsubo T; Kawaguchi S; Harada S; Tokioka S; Higuchi K
    BMC Gastroenterol; 2021 Nov; 21(1):432. PubMed ID: 34794376
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel endoscopic submucosal dissection technique for proton pump inhibitor-refractory gastroesophageal reflux disease.
    Ota K; Takeuchi T; Harada S; Edogawa S; Kojima Y; Inoue T; Higuchi K
    Scand J Gastroenterol; 2014 Dec; 49(12):1409-13. PubMed ID: 25384555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frontiers in Endoscopic Treatment for Gastroesophageal Reflux Disease.
    Ota K; Takeuchi T; Higuchi K; Sasaki S; Mori Y; Tanaka H; Hakoda A; Sugawara N; Iwatsubo T; Nishikawa H
    Digestion; 2024; 105(1):5-10. PubMed ID: 37591209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New treatment method for refractory gastroesophageal reflux disease (GERD): C-BLART (clip band ligation anti-reflux therapy)-a short-term study.
    Liu S; Chai N; Zhai Y; Zou J; Feng X; Li Z; Li L; Zhang X; Wang X; Wang S; Linghu EQ
    Surg Endosc; 2020 Oct; 34(10):4516-4524. PubMed ID: 31728750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized controlled trial of transoral incisionless fundoplication vs. proton pump inhibitors for treatment of gastroesophageal reflux disease.
    Witteman BP; Conchillo JM; Rinsma NF; Betzel B; Peeters A; Koek GH; Stassen LP; Bouvy ND
    Am J Gastroenterol; 2015 Apr; 110(4):531-42. PubMed ID: 25823768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of an endoscopic suturing device (the "ESD") to treat patients with gastroesophageal reflux disease, after unsuccessful EndoCinch endoluminal gastroplication: another failure.
    Schiefke I; Neumann S; Zabel-Langhennig A; Moessner J; Caca K
    Endoscopy; 2005 Aug; 37(8):700-5. PubMed ID: 16032486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characteristics of refractory gastroesophageal reflux disease (GERD) symptoms -is switching proton pump inhibitors based on the patient's CYP2C19 genotype an effective management strategy?
    Takeuchi T; Oota K; Harada S; Edogawa S; Kojima Y; Sanomura M; Sakaguchi M; Hayashi K; Hongoh Y; Itabashi T; Kitae H; Hoshimoto M; Takeuchi N; Higuchi K
    Intern Med; 2015; 54(2):97-105. PubMed ID: 25742999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pilot study on anti-reflux mucoplasty: Advancing endoscopic anti-reflux therapy for gastroesophageal reflux disease.
    Inoue H; Yamamoto K; Shimamura Y; Azuma D; Ushikubo K; Okada H; Kimoto Y; Nishikawa Y; Tanaka I; Tanabe M; Onimaru M; Navarro MJ
    Dig Endosc; 2024 Jun; 36(6):690-698. PubMed ID: 37899073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endoscopic treatment of proton pump inhibitor-refractory gastroesophageal reflux disease with anti-reflux mucosectomy: Experience of 109 cases.
    Sumi K; Inoue H; Kobayashi Y; Iwaya Y; Abad MRA; Fujiyoshi Y; Shimamura Y; Ikeda H; Onimaru M
    Dig Endosc; 2021 Mar; 33(3):347-354. PubMed ID: 32415898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of correlation between gastroesophageal reflux disease symptoms and esophageal lesions after sleeve gastrectomy.
    Soricelli E; Casella G; Baglio G; Maselli R; Ernesti I; Genco A
    Surg Obes Relat Dis; 2018 Jun; 14(6):751-756. PubMed ID: 29571635
    [TBL] [Abstract][Full Text] [Related]  

  • 11. More severe upper gastrointestinal symptoms associated with non-erosive reflux disease than with erosive gastroesophageal reflux disease during maintenance proton pump inhibitor therapy.
    Kusano M; Hosaka H; Kawamura O; Kawada A; Kuribayashi S; Shimoyama Y; Yasuoka H; Mizuide M; Tomizawa T; Sagawa T; Sato K; Yamada M
    J Gastroenterol; 2015 Mar; 50(3):298-304. PubMed ID: 24919745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short and long term effect of anti-reflux mucosectomy with cap-assisted endoscopic mucosal resection for refractory gastroesophageal disease.
    Lee YS; Kim JH; Yon DK; Yoo IK
    Surg Endosc; 2024 Apr; 38(4):2180-2187. PubMed ID: 38448622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of Vonoprazan, a Novel Potassium-Competitive Acid Blocker, in Patients with Proton Pump Inhibitor-Refractory Acid Reflux.
    Akiyama J; Hosaka H; Kuribayashi S; Moriyasu S; Hisada Y; Okubo H; Watanabe K; Imbe K; Nagata N; Kojima Y; Yokoi C; Uemura N; Shimoyama Y; Kawamura O; Yamada M; Kusano M
    Digestion; 2020; 101(2):174-183. PubMed ID: 30897577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ARE THE PERSISTENT SYMPTOMS TO PROTON PUMP INHIBITOR THERAPY DUE TO REFRACTORY GASTROESOPHAGEAL REFLUX DISEASE OR TO OTHER DISORDERS?
    Azzam RS
    Arq Gastroenterol; 2018 Nov; 55Suppl 1(Suppl 1):85-91. PubMed ID: 30304291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The role of the traditional surgical procedures for gastroesophageal reflux disease cannot be ignored].
    Zhou JH; Tan QY
    Zhonghua Wai Ke Za Zhi; 2020 Sep; 58(9):672-676. PubMed ID: 32878412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endoscopic management of gastroesophageal reflux disease: Panacea for proton pump inhibitors dependent/refractory patients.
    Kalapala R; Singla N; Reddy DN
    Dig Endosc; 2022 May; 34(4):687-699. PubMed ID: 34651353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endoscopic full-thickness plication for the treatment of PPI-dependent GERD: results from a randomised, sham controlled trial.
    Kalapala R; Karyampudi A; Nabi Z; Darisetty S; Jagtap N; Ramchandani M; Gupta R; Lakhtakia S; Goud R; Venkat Rao G; Sharma P; Reddy DN
    Gut; 2022 Apr; 71(4):686-694. PubMed ID: 33849942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gastroesophageal Reflux Disease: Pathophysiology and New Treatment Trends.
    Kasugai K; Ogasawara N
    Intern Med; 2024 Jan; 63(1):1-10. PubMed ID: 36927966
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The early therapeutic response at 2 weeks is a crucial predictor of proton pump inhibitor-refractory gastroesophageal reflux disease.
    Ogawa M; Arihiro S; Matsuhashi N; Joh T; Higuchi K; Iwakiri K; Kamiya T; Manabe N; Isshi K; Nakada T; Hokari A; Saruta M; Oshio A; Haruma K; Nakada K
    Esophagus; 2021 Apr; 18(2):398-406. PubMed ID: 33136239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Esophageal mucosal breaks in gastroesophageal reflux disease partially responsive to proton pump inhibitor therapy.
    Shaheen NJ; Denison H; Björck K; Silberg DG
    Am J Gastroenterol; 2013 Apr; 108(4):529-34. PubMed ID: 23318482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.